Variables related to TLS for the overall cohort and patients who developed TLS
| Variable (before venetoclax) . | Overall cohort, N = 81 (%) . | Patients with TLS, n = 10 (%) . |
|---|---|---|
| ALC (cells per uL), ≥25 000 | 5 (6.2) | 2 (20.0) |
| Any lymph node >5 cm | 26 (35.6) | 3 (42.9) |
| Any lymph node >10 cm | 6 (8.3) | 0 |
| Spleen size, median (range), cm | 16 (12-30) | 18 (15-27) |
| TLS risk | ||
| Low | 45 (60.8) | 3 (30.0) |
| Intermediate | 24 (32.4) | 5 (50.0) |
| High | 5 (6.8) | 0 |
| Venetoclax starting dose, mg | ||
| 20 | 66 (84.6) | 8 (88.9) |
| 50 | 7 (9.0) | 1 (11.1) |
| 100 | 2 (2.6) | 0 |
| ≥200 | 3 (3.8) | 0 |
| Inpatient monitoring for TLS | ||
| Yes, for the first dose level only | 14 (17.7) | 2 (20.0) |
| Yes, for the first 2 dose levels only | 12 (15.2) | 1 (10.0) |
| Yes, for ≥3 dose levels | 16 (20.3) | 4 (40.0) |
| No | 37 (46.8) | 3 (30.0) |
| Prophylactic allopurinol administered | 71 (89.9) | 9 (90.0) |
| Prophylactic IV fluids administered | 51 (67.1) | 9 (90.0) |
| Venetoclax dose at which TLS occurred, mg | ||
| 20 | — | 7 (77.8) |
| 50 | 2 (22.2) | |
| Venetoclax combined with other agent(s) | ||
| Combination | 31 (38.2) | 3 (30.0) |
| Venetoclax monotherapy | 50 (61.7) | 7 (70.0) |
| TLS-related biochemical abnormalities | ||
| Peak potassium, mmol/L | ||
| Median (range) | — | 4.8 (4.4-7.1) |
| ≥6 | 3 (30.0) | |
| Peak phosphorus, mg/dL | ||
| Median (range) | 5.6 (3.2-11.0) | |
| ≥4.5 | 8 (80.0) | |
| Peak uric acid, mg/dL | ||
| Median (range) | 6.8 (3.5-12.3) | |
| ≥8 | 4 (40.0) | |
| Nadir calcium, mg/dL | ||
| Median (range) | 7.8 (6.6-8.7) | |
| ≤7 | 4 (40.0) | |
| Peak creatinine, mg/dL | ||
| Median (range) | 1.5 (0.7-6.2) | |
| ≥2 | 3 (30.0) | |
| Received rasburicase | — | 6 (60) |
| Variable (before venetoclax) . | Overall cohort, N = 81 (%) . | Patients with TLS, n = 10 (%) . |
|---|---|---|
| ALC (cells per uL), ≥25 000 | 5 (6.2) | 2 (20.0) |
| Any lymph node >5 cm | 26 (35.6) | 3 (42.9) |
| Any lymph node >10 cm | 6 (8.3) | 0 |
| Spleen size, median (range), cm | 16 (12-30) | 18 (15-27) |
| TLS risk | ||
| Low | 45 (60.8) | 3 (30.0) |
| Intermediate | 24 (32.4) | 5 (50.0) |
| High | 5 (6.8) | 0 |
| Venetoclax starting dose, mg | ||
| 20 | 66 (84.6) | 8 (88.9) |
| 50 | 7 (9.0) | 1 (11.1) |
| 100 | 2 (2.6) | 0 |
| ≥200 | 3 (3.8) | 0 |
| Inpatient monitoring for TLS | ||
| Yes, for the first dose level only | 14 (17.7) | 2 (20.0) |
| Yes, for the first 2 dose levels only | 12 (15.2) | 1 (10.0) |
| Yes, for ≥3 dose levels | 16 (20.3) | 4 (40.0) |
| No | 37 (46.8) | 3 (30.0) |
| Prophylactic allopurinol administered | 71 (89.9) | 9 (90.0) |
| Prophylactic IV fluids administered | 51 (67.1) | 9 (90.0) |
| Venetoclax dose at which TLS occurred, mg | ||
| 20 | — | 7 (77.8) |
| 50 | 2 (22.2) | |
| Venetoclax combined with other agent(s) | ||
| Combination | 31 (38.2) | 3 (30.0) |
| Venetoclax monotherapy | 50 (61.7) | 7 (70.0) |
| TLS-related biochemical abnormalities | ||
| Peak potassium, mmol/L | ||
| Median (range) | — | 4.8 (4.4-7.1) |
| ≥6 | 3 (30.0) | |
| Peak phosphorus, mg/dL | ||
| Median (range) | 5.6 (3.2-11.0) | |
| ≥4.5 | 8 (80.0) | |
| Peak uric acid, mg/dL | ||
| Median (range) | 6.8 (3.5-12.3) | |
| ≥8 | 4 (40.0) | |
| Nadir calcium, mg/dL | ||
| Median (range) | 7.8 (6.6-8.7) | |
| ≤7 | 4 (40.0) | |
| Peak creatinine, mg/dL | ||
| Median (range) | 1.5 (0.7-6.2) | |
| ≥2 | 3 (30.0) | |
| Received rasburicase | — | 6 (60) |
Missing data for overall cohort: lymph node >5 cm, n = 8; lymph node >10 cm, n = 9; spleen size, n = 54; TLS risk, n = 7; venetoclax starting dose, n = 3; inpatient monitoring for TLS, n = 2; prophylactic allopurinol given, n = 2; and prophylactic IV fluids given, n = 5.
Missing data for patients with TLS: lymph node >5 cm, n = 3; lymph node >10 cm, n = 3; spleen size, n = 6; TLS risk, n = 2; venetoclax starting dose, n = 1; and venetoclax dose at which TLS occurred, n = 1.